Elon Musk says users on X, formerly Twitter, will lose ability to block unwanted followers, eliminating key safety feature
Elon Musk said on Friday that users of the site formerly known as Twitter will no longer be able to block unwanted followers from responding to their posts.
How Modelo dethroned Bud Light to become the top-selling U.S. beer
How Modelo overtook Bud Light’s spot as America’s bestselling beer
Hunter Biden misdemeanor tax charges are dismissed — for now
Special counsel David Weiss is expected to refile the charges or bring new ones against the president’s son in California or Washington, D.C.
‘Tip fatigue’ is real. Here’s when to leave 20%, and when it’s OK to leave less
Consumers are encouraged to tip generously but most don’t.
Trump team seeks to delay federal election interference trial until 2026
Former President Donald Trump wants a federal judge to reject special counsel Jack Smith’s request to get the trial underway in early January of next year.
Hawaii tapping outside investigator as wildfire response scrutiny grows
The decision to hire an outside investigator comes as questions mount over whether emergency officials did enough to warn residents in Maui about the wildfires.
Moderna says new Covid vaccine was effective against Eris variant in early trial
Moderna’s vaccine and new shots from Pfizer and Novavax are slated to roll out within weeks, pending potential approvals from the Food and Drug Administration.
The scientist behind IBM Watson has raised $60 million for his AI startup in New York
David Ferrucci, who led the team behind IBM Watson, raised nearly $60 million in funding for his AI startup, Elemental Cognition, according to an SEC filing.
Trump keeps sounding off on his indictments. His attacks could hasten the criminal trials
Trump’s aggressive and targeted criticism related to his criminal indictments has prompted some legal experts to predict that he may face a gag order.
Weight-loss drugs are priced substantially higher in the U.S. than in other countries, analysis says
The KFF analysis comes as many U.S. health insurers balk at the extreme cost of weight-loss drugs and drop the medications from their plans.
